Key result
Statin pre-therapy in percutaneous coronary intervention may offer myocardial protection through pleiotropic effects, as reviewed across major randomized trials.
Why the study?
Does pre-treatment with statins improve procedural outcomes and reduce myocardial injury in patients undergoing percutaneous coronary intervention?
Does pre-treatment with statins improve procedural outcomes and reduce myocardial injury in patients undergoing percutaneous coronary intervention?
This review highlights the potential of statin pre-treatment to reduce periprocedural myocardial injury during PCI via non-lipid, pleiotropic mechanisms.
Answers are grounded in this paper and cite their sources.
Statin pre-treatment may warrant consideration before PCI to limit injury; leaves open confirmation of pleiotropic benefits in dedicated trials.
Statins present a number of beneficial effects on endothelial function and atherosclerotic plaque, modulating oxidative stress and inflammation. The benefits of long-term statin treatment in the entire spectrum of atherosclerotic vascular disease can largely be explained by its cholesterol-lowering effects and the associated reduction of the progression of atherosclerosis. The short-term benefits of statins use are most likely due to their non-lipid, pleiotropic effects. Myocardial injury during percutaneous coronary intervention (PCI) occurs in 10-40% of cases and is often characterized by a slight increase in the markers of myocardial necrosis, sometimes without symptoms, electrocardiographic changes or impairment of cardiac function. Periprocedural myocardial infarction is associated with a worse outcome on long term follow-up. Several randomized trials have suggested a beneficial effect of pre-treatment with statins in the outcome of the procedure. Myocardial protection by statin pre-therapy in PCI has been studied in several trials published over the last decade. The mechanisms underlying the beneficial pleiotropic effects of statins may be an anti-inflammatory action reducing myocardial injury necrosis due to microembolization, an improvement in endothelial function on microcirculation, and direct myocardial protection. This article reviews the major randomized trials which have studied the use of statins as pre-treatment in PCI and explores future perspectives.
No takes yet. Share an insight, caveat, or question.
Bronis et al. (2011) conducted a review in Percutaneous coronary intervention. Statins was evaluated. Statin pre-therapy in percutaneous coronary intervention may offer myocardial protection through pleiotropic effects, as reviewed across major randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: